Anti-SLAMF7 therapeutic antibodies have been developed, like humanized Elotuzumab mAb which obtained FDA approval to treat MM cases in combination with lenalidomide and dexamethasone medications [129]. Here, SLAMF7 is linked to Miyoshi myopathy.